The global transdermal drug delivery systems market size was valued at $52,476.5 million in 2020, and is projected to reach $87,322.4 million by 2030, registering a CAGR of 4.9% from 2021 to 2030. Transdermal drug delivery systems are dosage forms that are designed to deliver an effective amount of drug across a patient's skin. The adhesive used in transdermal drug delivery systems govern the safety, efficiency, and quality of the product.
Transdermal drug delivery systems are capable of maintaining adequate concentration of medicine in the blood for a long period of time. These systems can also reduce the chances of systemic adverse reactions, such as gastrointestinal tract disorders.
The increase in number of patients suffering from chronic diseases, such as heart diseases, diabetes, and arthritis has significantly increased owing to lifestyle changes and stressful work culture. Furthermore, the global geriatric population is also on the rise. These factors positively influence the growth of the market. However, side-effects caused by the use of transdermal drug delivery systems can restraint the market growth. Advancements in technologies enable the use of transdermal systems for delivering a wide range of drugs.
The transdermal drug delivery systems market is segmented on the basis of type of delivery, application, and region. By type of delivery, the market is classified into passive and active.. By application, it is categorized into analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market
The major market participants profiled in this report include Altaris, Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Novartis AG, Purdue Pharma L.P. and Viatris Inc.
Transdermal drug delivery systems are capable of maintaining adequate concentration of medicine in the blood for a long period of time. These systems can also reduce the chances of systemic adverse reactions, such as gastrointestinal tract disorders.
The increase in number of patients suffering from chronic diseases, such as heart diseases, diabetes, and arthritis has significantly increased owing to lifestyle changes and stressful work culture. Furthermore, the global geriatric population is also on the rise. These factors positively influence the growth of the market. However, side-effects caused by the use of transdermal drug delivery systems can restraint the market growth. Advancements in technologies enable the use of transdermal systems for delivering a wide range of drugs.
The transdermal drug delivery systems market is segmented on the basis of type of delivery, application, and region. By type of delivery, the market is classified into passive and active.. By application, it is categorized into analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market
Competition Analysis
The major market participants profiled in this report include Altaris, Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Novartis AG, Purdue Pharma L.P. and Viatris Inc.
Key Benefits For Stakeholders
- The report provides an extensive analysis of the current and emerging transdermal drug delivery systems market trends and dynamics.
- In-depth market analysis is conducted by constructing market estimations for the key Market Segment between 2020 and 2030.
- Extensive analysis of the transdermal drug delivery systems market is conducted by following key product positioning and monitoring of the top competitors within the market framework.
- A comprehensive analysis of all regions is provided to determine the prevailing opportunities.
- The global transdermal drug delivery systems market forecast analysis from 2021 to 2030 is included in the report.
- The key market players within transdermal drug delivery systems market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the transdermal drug delivery systems industry.
Key Market Segments
BY TYPE OF DELIVERY SYSTEM
- Passive
- Active
BY APPLICATION
- Analgesics
- Hormone Replacement Therapies
- Hypertension
- Motion Sickness
- Smoking Cessation
- Others
BY REGION
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Key Market Players
- Viatris Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Endo International plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Purdue Pharma L.P.
- Altaris
- Hisamitsu Pharmaceutical Co. Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM
CHAPTER 5: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
CHAPTER 6: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
CHAPTER 7: COMPANY LANDSCAPE
CHAPTER 8: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Transdermal Drug Delivery Systems Market,' the transdermal drug delivery systems market size was $52.5 billion in 2020, and is estimated to reach $87.3 billion by 2030, growing at a CAGR of 4.9% from 2021 to 2030.The rise in global geriatric population has significantly increased the demand for efficient and effective drug delivery systems. Furthermore, changing work culture and lifestyle across the globe has significantly increased the number of patients suffering from chronic diseases such as heart diseases, diabetes, and arthritis. In addition, advancements in transdermal drug delivery systems have enabled in use for delivery a wide range of medicines. Also, major companies in the industry are focused on development of more advanced and efficient transdermal drug delivery systems.
By type of delivery, the market is segmented into passive and active. Among these, the passive segment accounted for the highest transdermal drug delivery systems market share in 2020 and active segment is expected to witness significant growth during the forecast period, owing to increase in demand for geriatric medicines and increase in healthcare spending. The market is analyzed with respect to different applications in industrial verticals, such as analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation and others. The market is mainly driven by growth of global pharmaceutical industry, rise in geriatric population, and significant increase in patients suffering from chronic diseases across the globe. However, side-effects can constraint the transdermal drug delivery systems market growth.
In 2020, North America dominated the global transdermal drug delivery systems market, in terms of revenue, accounting for around 41% share of the transdermal drug delivery systems industry, followed by Europe and Asia-Pacific. Moreover, the market in Asia-Pacific region is growing with high CAGR, owing to rise in healthcare spending and efficiency of transdermal drug delivery systems.
Furthermore, on the basis of application, the motion sickness segment is anticipated to grow rapidly, with a CAGR of 6.3% during the forecast period, owing to rise in number of patients suffering from chronic diseases and rapid growth of pharmaceutical industry.
For instance, according to India Brand Equity Foundation, India is the largest provider of generic drugs and has a large network of 3,000 drug companies and over 10,500 manufacturing units. Furthermore, in August 2021, the Indian pharmaceutical market registered an annual growth rate of 17.7%, up from 13.7% in July 2020. The India’s drugs and pharmaceuticals exports reached US$ 24.44 billion in FY21. In addition, in June 2021, the Ministry of Finance, allocated26,578.3 million over the next five years for the pharmaceutical PLI scheme.
However, during the COVID-19 pandemic lockdown, various players in the transdermal drug delivery systems market reduced their business in countries, such as China, the U.S., and India owing to disruption of supply chain. This break directly impacted the transdermal drug delivery systems manufacturing companies. In addition, extensive focus of major countries on development of vaccines also negatively influenced the growth of the market. However, reopening of production facilities and introduction of vaccines for coronavirus disease are anticipated to boost the transdermal drug delivery systems market growth.
Key Findings of the Study
- The report provides an extensive analysis of the current and emerging transdermal drug delivery systems market trends and dynamics.
- Depending on type of delivery, the passive dominated the transdermal drug delivery systems market, in terms of revenue in 2020 and the active segment is projected to grow at a significant CAGR during the forecast period.
- By application, the analgesics segment registered highest revenue in 2020.
- Asia-Pacific is projected to register highest growth rate in the coming years.
The report provides an extensive analysis of the current trends and emerging opportunities of the market.
In-depth transdermal drug delivery systems market share analysis is conducted by constructing estimations for the key segments between 2021 and 2030.
Companies Mentioned
- Viatris Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Endo International plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Purdue Pharma L.P.
- Altaris
- Hisamitsu Pharmaceutical Co. Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 52476.5 million |
| Forecasted Market Value ( USD | $ 87322.4 million |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
